The EANM practice guidelines for bone scintigraphy by unknown
GUIDELINES
The EANM practice guidelines for bone scintigraphy
T. Van den Wyngaert1,2 & K. Strobel3 & W. U. Kampen4 & T. Kuwert5 &
W. van der Bruggen6 & H. K. Mohan7 & G. Gnanasegaran8 &
R. Delgado-Bolton9 & W. A. Weber10 & M. Beheshti11 &
W. Langsteger11 & F. Giammarile12 & F. M. Mottaghy13,14 & F. Paycha15 &
On behalf of the EANM Bone & Joint Committee and the Oncology Committee.
Received: 2 May 2016 /Accepted: 3 May 2016 /Published online: 4 June 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Purpose The radionuclide bone scan is the cornerstone of
skeletal nuclear medicine imaging. Bone scintigraphy is a
highly sensitive diagnostic nuclear medicine imaging tech-
nique that uses a radiotracer to evaluate the distribution of
active bone formation in the skeleton related to malignant
and benign disease, as well as physiological processes.
Methods The European Association of Nuclear Medicine
(EANM) has written and approved these guidelines to pro-
mote the use of nuclear medicine procedures of high quality.
Conclusion The present guidelines offer assistance to nuclear
medicine practitioners in optimizing the diagnostic procedure
and interpreting bone scintigraphy. These guidelines describe
the protocols that are currently accepted and used routinely,
but do not include all existing procedures. They should
therefore not be taken as exclusive of other nuclear medicine
modalities that can be used to obtain comparable results. It is
important to remember that the resources and facilities avail-
able for patient care may vary.
Keywords Bone scintigraphy . Bone scan . Bone SPECT/
CT . Bone disease
Preamble
The aim of this document is to provide general information
about bone scintigraphy. This guidelines describe current rou-
tine clinical procedures but should not be interpreted as
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excluding alternative procedures also employed to obtain
equivalent data. It is important to remember that the resources
and facilities available for patient care may vary from one
country to another and from one medical institution to another.
This document has been prepared primarily for nuclear medi-
cine physicians, physicists and technicians with the intention of
offering assistance in optimizing procedural protocols and di-
agnostic information that can currently be obtained from bone
scintigraphy. The guidelines were written by the EANM Bone
& Joint and Oncology Committees and then reviewed and
approved by all EANM committees and the Board, as well as
by the National Societies represented within the EANM.
The EANM wrote and approved the guidelines to promote
the use of high-quality nuclear medicine procedures. These
guidelines are intended to assist practitioners in providing ap-
propriate nuclear medicine care for patients. They are not in-
flexible rules or requirements for practice and are not intended,
nor should they be used, to establish a legal standard of care.
For these reasons and those set out below, the EANM cautions
against the use of these guidelines in litigation in which the
clinical decisions of a practitioner are called into question.
The ultimate judgment regarding the propriety of any specific
procedure or course of action must be made by medical profes-
sionals taking into account the unique circumstances of each
case. Thus, an approach that differs from the guidelines does
not necessarily imply that the approach was below the standard
of care. To the contrary, a conscientious practitioner may respon-
sibly adopt a course of action different from that set out in the
guidelines when, in the reasonable judgment of the practitioner,
such course of action is indicated by the condition of the patient,
the limitations of available resources, or advances in knowledge
or technology subsequent to publication of the guidelines.
The practice of medicine involves not only the science, but
also the art of dealing with the prevention, diagnosis, allevia-
tion, and treatment of disease. The variety and complexity of
human conditions make it impossible at times to identify the
most appropriate diagnosis or to predict with certainty a par-
ticular response to treatment. Therefore, it should be recog-
nized that adherence to these guidelines will not assure an
accurate diagnosis or a successful outcome. All that should
be expected is that the practitioner will follow a reasonable
course of action based on current knowledge, available re-
sources, and the needs of the patient to deliver effective and
safe medical care. The sole purpose of these guidelines is to
assist practitioners in achieving this objective.
Introduction and goals
The radionuclide bone scan is the cornerstone of skeletal nu-
clear medicine imaging. Bone scintigraphy is a highly sensitive
diagnostic nuclear medicine imaging technique that uses a ra-
diotracer to evaluate the distribution of active bone formation in
the skeleton related tomalignant and benign diseases, as well as
physiological processes. Phosphate analogues can be labelled
with technetium-99m (99mTc) and are used for bone imaging
because of their high uptake in the skeleton and rapid clearance
from soft tissues after intravenous injection. Tracer accumula-
tion occurs in proportion to local blood flow and bone remod-
elling activity (dependent on osteoblast/osteoclast activity), and
unbound tracer is rapidly cleared from surrounding soft tissues.
Most pathological bone conditions, whether of infectious,
traumatic, neoplastic or other origin, are associated with an
increase in vascularization and local bone remodelling. This
accompanying bone reaction is reflected on bone scans as a
focus of increased radioactive tracer uptake. Bone scintigra-
phy is a sensitive technique that can detect significant meta-
bolic changes very early, often several weeks or even months
before they become apparent on conventional radiological im-
ages. In addition, the technique provides an overview of the
entire skeleton at a relatively modest radiation exposure.
While MRI has been shown to be more sensitive than pla-
nar bone scans in detecting skeletal metastases in vertebral
bodies, bone SPECT has been found to have comparable di-
agnostic sensitivity for vertebral body metastases and a higher
diagnostic sensitivity for metastases located in the pedicles
[1]. Furthermore, the majority of studies that have compared
bone scanning with MRI did not use a reliable gold standard
and typically included various solid tumours and even lym-
phomas which usually produce osteolytic lesions with poor
osteoblastic bone reaction so that they are not detectable by
bone scintigraphy. Hence, there is no reliable evidence that
bone scintigraphy is generally less sensitive than whole-
body MRI in all solid cancers. Multimodality SPECT/CT of-
fers the unique opportunity to correlate scintigraphic findings
with anatomical images and introduces novel algorithms to
further enhance SPECT image quality based on the CT data
(e.g. correction for attenuation and scatter). This results in
improved correlation of areas with physiological variants or
abnormal tracer accumulation with anatomical landmarks [2].
However, this has increased the complexity of this technique,
increasing the need for standardization and practice guidelines
in order to maximize the diagnostic yield of the examination.
The corresponding guidelines from the Society of Nuclear
Medicine and Molecular Imaging (SNMMI), the Dutch
Society of Nuclear Medicine (NVNG), and the French
Society of Nuclear Medicine and Molecular Imaging
(SFMN), as well as the existing EANM bone scintigraphy
procedures guideline for tumour imaging were consulted
while preparing this consensus document [3–6]. For specific
applications of bone scintigraphy in selected indications or
populations, the reader is also referred to the EANM guide-
lines for paediatric bone scanning, and the EANM and
SNMMI practice guidelines for sodium 18F-fluoride PET/CT
bone scans [7–9]. Other excellent reference works are also
recommended [10].
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The goal of these guidelines is to provide an educational
tool designed to assist the nuclear medicine practitioner in
appropriately recommending, performing, interpreting, and
reporting the results of bone scintigraphy.
Definitions
1. Planar whole-body images in the anterior and posterior
projections of the axial and appendicular skeleton. If nec-
essary, additional localized or spot views can be obtained.
2. Focal planar images limited to a specific portion of the
skeleton.
3. Single photon emission tomography (SPECT, also known
as SPET) allows the visualization of the three-
dimensional distribution of the radiopharmaceutical in
the skeleton.
4. SPECT/CT images consist of a SPECT acquisition com-
bined with CT using an integrated CT scanner.
5. Multiphase bone scan produces planar images of the vas-
cular inflow and the soft tissue phase, and delayed phase
images of the radiopharmaceutical over a given area of the
skeleton. The vascular inflow images are acquired during
intravenous injection. The study of the soft tissue distri-
bution of the radiopharmaceutical in the region of interest
is performed within the first 5–10 min after injection.
Finally, delayed whole-body, focal views, and/or tomo-
graphic images are usually acquired between 2 and 4 h
after injection of the radiopharmaceutical. In some pa-
tients, it may be useful to acquire late-phase images up
to 24 h after tracer administration [11].
6. Quantification is the process of calculating the osseous
radioactivity concentration expressed as standardized up-
take values (SUV).
Common clinical indications for bone scan
The indications for bone scintigraphy are numerous and can
generally be classified into three distinct clinical scenarios: (1)
when a specific bone disease is present or suspected, (2) to
explore unexplained symptoms, and (3) for the metabolic as-
sessment prior to the start of therapy. While the diagnostic
sensitivity of bone scintigraphy is very high, the low specific-
ity often requires further investigation with other imaging mo-
dalities (e.g. plain radiography, CT or MRI) or nuclear medi-
cine studies (e.g. FDG PET/CT). For this reason, anatomical
imaging and bone scintigraphy should be considered as com-
plementary methods, each of which cannot be replaced by the
other.
Conversely, bone scintigraphy is not indicated in a number
of specific conditions due to limitations of the technique in a
specific disease context or lack of clinical impact of imaging
results. However, ultimately it must be the nuclear medicine
physician who evaluates and decides on the indication in each
particular case and on the specific protocol that should be
applied. Both indications and nonrecommended indications
are outlined in the following sections.
Bone disease present or suspected
1. Oncology
& Solid tumours with high affinity for bone, including
prostate, breast, lung and renal cancer [12–17]
& Malignant haematological conditions limited to bone,
including Hodgkin’s disease and non-Hodgkin’s lym-
phoma [18]
& Bone tumours and bone dysplasia, including osteosar-
coma, osteoid osteoma, osteoblastoma, fibrous dys-
plasia, giant cell tumour and osteopoikilosis [19]
& Soft tissue sarcomas, including rhabdomyosarcoma
& Paraneoplastic syndromes, including hypertrophic
pulmonary osteoarthropathy, algodystrophy,
polymyalgia rheumatica, poly(dermato)myositis and
osteomalacia





Whole-body FDG PET and PET/CT are other im-
aging modalities that enable detection of the primary
tumour and metastases by visualization of the in-
creased glucose consumption of malignant tissue.
The majority of studies comparing FDG PET with
18F-fluoride PET or SPECT with 99mTc-labelled
bisphosphonates have shown a higher diagnostic sen-
sitivity of FDG for osteolytic metastases and a higher
diagnostic sensitivity of bone-affine radiotracers for
detecting osteoblastic metastases [20–24].
Primary tumours of bone are relatively rare in
adults, whereas bone metastases of other cancer enti-
ties (e.g. breast, prostate, lung, renal cancer, etc.) are
very frequent. In prostate cancer, the assessment of
bone scans is increasingly standardized by calculation
of the bone scan index and reporting of progression
according to PCWG-2 criteria [25, 26].
2. Rheumatology
& Chronic inflammatory arthritis, including rheumatoid
arthritis, spondyloarthropathies and related disorders
(ankylosing spondylitis, psoriatic arthritis, Reiter’s ar-
thritis, SAPHO syndrome [synovitis, acne, pustulosis,
hyperostosis, osteitis], chronic recurrent multifocal
osteomyelitis) and sacroiliitis [27–29]
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& Osteoarthritis of the lumbar facet joints, hip,
femorotibial and femoropatellar osteoarthritis,
rhizarthrosis and tarsal osteoarthritis [30, 31]
& Enthesopathies, including plantar fasciitis, Achilles
tendinitis and bursitis
& (Avascular) osteonecrosis, which is most frequently
located at the femoral head, femoral condyle and tib-
ial plateau
& Osteonecrosis of the jaw (ONJ) [32]
& Complex regional pain syndrome type I of the hand,
hip, knee and foot
& Tietze’s syndrome (costochondritis)
& Polymyositis
& Paget’s disease
& Langerhans cell histiocytosis (LCH): single system
LCH and multisystem LCH with bone involvement
& Non-Langerhans cell diseases, such as Erdheim–
Chester disease, Schnitzler syndrome, and Rosaï
Dorfman disease
& Other rare osteoarticular diseases, such as sarcoidosis
with bone involvement, mastocytosis, Behçet’s dis-
ease, and familial Mediterranean fever
3. Bone and joint infections [33]
& Osteomyelitis (acute, subacute or chronic, of bacteri-
al, mycobacterial or fungal origin)
& Septic arthritis
& Spondylodiscitis or spondylitis
& Septic loosening or mechanical complication of inter-
nal fixation (long bones or spine) or arthroplasty (hip,
knee, ankle or shoulder)
& Malignant (necrotizing) external otitis
The reader is also referred to other relevant EANM
consensus documents and guidelines [34, 35].
4. Orthopaedics, sports and traumatology [36, 37]
& Periostitis, including shin splints and thigh splints
[38]
& Enthesopathies, including plantar fasciitis, Achilles
tendinitis and bursitis
& Spondylolisthesis (acute or subacute)
& Radiological occult stress-related fractures (e.g.
scaphoid, tarsals) or nonspecific symptoms [39]
& Insufficiency fractures, including osteoporotic verte-
bral or occult fractures, sacral fractures, femoral head
or neck fractures, tibial plateau fractures, tarsal and
metatarsal fractures
& Septic loosening, mechanical complication, and syno-
vitis of internal fixation (long bones or spine) or pros-
thesis (hip, knee, ankle, or shoulder)
& Pseudoarthrosis (delayed union, non-union)
& Periarticular heterotopic ossification
& Viability of bone graft
5. Metabolic bone disease [40–42]
& Hyperparathyroidism (primary and secondary)
& Osteomalacia
& Renal osteodystrophy
& Rare skeletal manifestations of endocrine disorders,
including hyperthyroidism and acromegaly
& Vitamin D deficiency
6. Paediatrics
& Osteochondritis of the hip (Legg-Calvé-Perthes
disease)
& Transient synovitis of the hip
& Osteoid osteoma
& Battered child syndrome
& Mandibular condylar hyperplasia
& Bone infarction (sickle cell disease, thalassaemia)
Exploration of unexplained symptoms
1. Subacute or chronic musculoskeletal or bone pain with
normal clinical examination and radiographs
& Arthralgia, monoarthritis, oligoarthritis, polyarthritis,
localized or multifocal bone pain and backache
2. Further exploration of abnormal biochemical (e.g. phos-
phate or calcium metabolism) or radiological findings
3. Fever of unknown origin: exclusion of osteomyelitis
Metabolic assessment prior to initiation of therapy
1. Evaluation of the activity of arthropathies and to confirm
active synovitis prior to radiation synovectomy or before
infiltration of facet joints with corticosteroids
2. Evaluation of osteoblast activity in case of Paget’s disease
before initiating treatment with bisphosphonates
3. Assessment of benign or malignant vertebral compression
fracture prior to vertebroplasty or kyphoplasty
Treatment monitoring
Quantitative bone SPECT/CT is a novel technique with po-
tentially useful applications in treatment response monitoring
in bone [43]. However, the exact role in routine clinical prac-
tice has yet to be determined.
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Bone scan not indicated
Bone scan may not be the preferred investigation in the fol-
lowing conditions
1. Bone lesions with known inconsistent scintigraphic find-
ings, such as plasmacytoma, multiple myeloma,
chordoma, or Ewing’s sarcoma
2. Benign bone lesions and incidentalomas when properly
characterized by radiological imaging, including bone is-
land, uncomplicated haemangioma, osteitis condensans
ilii, nonossifying fibromas, asymptomatic enchondroma
of the long bones, ganglion cyst and asymptomatic
Paget’s disease
3. Symptomatic degenerative joint disease well character-
ized on radiological imaging, properly diagnosed based
on the pain syndrome and a well performed clinical
examination
Even though bone scintigraphy may in general not be the
preferred imaging modality in the conditions listed above, this
recommendation should be assessed within the specific clini-
cal context of the patient.
Specification of the examination procedure
Qualifications and responsibilities of personnel
All physicians and personnel involved in performing and
reporting bone scintigraphy should be sufficiently qualified
and experienced in accordance with applicable laws, and in-
dividual responsibilities should be documented in standard
operating procedures.
Request
The written or electronic request form should provide suffi-
cient information to demonstrate the medical necessity of the
examination. This should include current signs and symp-
toms, relevant history (skeletal surgery, trauma, or recent ra-
diation or chemotherapy), and the specific reason for the ex-
amination or provisional diagnosis. Outpatients should also
bring the results of all other relevant examinations that have
already been performed (laboratory, radiological, scintigraph-
ic, or other).
Patient preparation
When making an appointment, the patient should receive
information on how the examination is performed and its
estimated duration. Patients should be informed that they
may eat and drink and of the need to report a pregnancy,
any delay in menstrual cycle, or active breastfeeding.
Information leaflets and/or displays should be available in
the waiting area of the nuclear medicine service, and all
information should preferably be accessible through the
website of the institution.
Prior to tracer injection, the nuclear medicine physician or
technologist must explain the purpose of the examination, the
expected benefits, and answer any questions. The patient is
informed as to how the examination is to be performed (e.g.
multiple planar acquisitions, additional SPECT/CT, etc.), tak-
ing into account the specific clinical problem. Relevant infor-
mation that may assist in interpretation of imaging findings are
checked with the patient, including:
1. History of fractures, trauma, osteomyelitis, cellulitis, oe-
dema, arthritis, neoplasms, metabolic bone disease, or
limitation of function
2. Current symptoms and physical findings
3. Results of prior bone scintigraphy or other imaging stud-
ies such as conventional radiography, CT and MRI (it is
strongly recommended that hard copies or computer files
of previous examinations be obtained)
4. History of recent nuclear medicine studies
5. Laboratory results
6. History of therapy that might affect the results of bone
scintigraphy (see Precautions)
7. History and dates of prior orthopaedic surgery (e.g. pres-
ence and location of prosthetic implants)
8. History of anatomical or functional renal/urinary tract
abnormalities
9. Contraindications for hydration
At this time, the physical condition of the patient
should be assessed and whether current symptoms (e.g.
pain, immobility, etc.) may hamper acquisition of optimal
images. In patients with severe pain, an appropriate anal-
gesic strategy should be implemented in consultation with
the treating/referring physician. In addition, the scanning
parameters may be adapted to accommodate the patient
(see Protocol/image acquisition).
Unless contraindicated, patients should be well hydrated
and instructed to drink one or more litres of water during the
time between injection and imaging. All patients should be
asked to void their bladder frequently during the time between
injection and delayed imaging as well as immediately prior to
the scan. The patients should drink a large amount of fluids
during the 24 h after radiopharmaceutical administration. In
patients on renal replacement therapy, haemodialysis per-
formed from 15 min to 5 h after injection of the radiopharma-
ceutical can successfully decrease blood pool and soft tissue
activity to nearly normal levels [44, 45]. However, careful
planning of the examination and consultation with the treating
nephrologist are recommended.
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Precautions
Pregnancy and lactation
In women of childbearing age, it is necessary to verify the
absence of pregnancy. In a patient who is known or
suspected to be pregnant, a clinical decision is necessary
to consider the benefits against the possible harm of carry-
ing out any procedure. If medically justified, radiation ex-
posure should be delayed until after both pregnancy and
breastfeeding. Evaluation by other techniques such as ul-
trasonography or MRI is preferred. While interruption in
breastfeeding is not essential according to the ICRP, this is
on the basis that there is no free pertechnetate in the radio-
pharmaceutical [46]. Therefore, an interruption of at least
4 h during which one meal is discarded is advised to be on
the safe side.
Possible drug interactions
The main drugs that may interfere with the quality of scinti-
graphic images are:
1. Aluminium: reduced skeletal tracer uptake, diffuse hepat-
ic tracer uptake, increased renal tracer uptake
2. Androgen deprivation therapy for prostate cancer
(bicalutamide, oestrogens): increased mammary tracer
uptake in case of gynecomastia
3. Bone-modifying agents (including bisphosphonates and
denosumab) or agents interfering with osteoblast func-
tion (e.g. cabozantinib): reduced skeletal tracer uptake
[47]
4. Corticosteroids: reduced skeletal tracer uptake, reduced
tracer uptake at fracture sites
5. Haematopoietic growth factors: increased spinal tracer
uptake, possible increased tracer uptake in the appendic-
ular skeleton
6. Iron: increased renal tracer uptake, increased tracer uptake
at site of intramuscular injection, diffuse hepatic tracer
uptake
7. Methotrexate: diffuse hepatic tracer uptake
8. Nephrotoxic chemotherapy: increased renal tracer uptake
and reduced skeletal tracer uptake
9. Nifedipine: reduced skeletal tracer uptake
Radiopharmaceuticals
Physical characteristics of the radionuclide
99mTc decays by isomeric transition with a half-life of 6.02 h
to 99Tc by emitting one 140.5-keV gamma ray per decay.
Characteristics of the tracer molecule
The molecules most commonly used for performing bone
scintigraphy are bisphosphonates: methylene diphosphonate
(MDP), hydroxymethylene diphosphonate (HMDP) or
hydroxyethylene diphosphonate (HDP), and 2,3-
dicarboxypropane-1,1-diphosphonate (DPD).
Pharmacokinetics
The injected radiolabelled bisphosphonates adsorb to the sur-
face of hydroxyapatite crystals in proportion to local bone
vascularization and osteoblastic activity. After intravenous ad-
ministration, the plasma clearance of bisphosphonates is
biexponential and a function of skeletal uptake and urinary
elimination. Four hours after injection, approximately 50 to
60 % of the injected amount is fixed in the skeleton, the un-
bound fraction (34 %) is excreted in the urine, and only 6 %
remains in the circulation. Tracer elimination through the gas-
trointestinal tract is insignificant. Maximum bone accumula-
tion is reached 1 h after tracer injection and remains practically
constant up to 72 h.
Radiopharmaceutical preparation and storage
The bisphosphonates listed above are commercially available
and supplied in a vial containing the bisphosphonate, a stan-
nous reducing agent and other excipients in the form of a
powder ready for labelling. Vials containing the sterile
nonpyrogenic lyophilisate should be stored at 4–8 °C or room
temperature, as required by the manufacturer. These kits can
be used until the expiry date of the batch (1 to 2 years after the
date of manufacture).
The radiopharmaceutical is prepared by the addition of the
required amount of sodium pertechnetate [99mTcO4
−] diluted
in sterile physiological saline to the vial in accordance with the
manufacturer’s instructions. After labelling, the preparation
should be kept at between 4 °C and 8 °C or at room temper-
ature, depending on the brand used, and remains stable for 8 h.
Because the radiopharmaceutical is susceptible to oxidation,
care should be taken to avoid introducing air into the
multidose vial during preparation or removal of doses. The
radiopharmaceutical should be used within 6 h of preparation
unless allowed otherwise by the manufacturer.
Administered activity
The radiopharmaceutical has to be administered by the intra-
venous route, e.g. by direct intravenous injection, via an in-
dwelling catheter or using a butterfly needle.
The activity of the radiopharmaceutical to be administered
should be determined after taking into account Directive
2013/59/EURATOM of the Council of the European Union,
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which guarantees health protection of individuals with respect
to the dangers of ionizing radiation in the context of medical
exposure. According to this directive, member states are re-
quired to bring into force such regulations as may be neces-
sary to comply with the directive. One of the criteria is the
designation of Diagnostic Reference Levels (DRL) for radio-
pharmaceuticals; these are defined as levels of activity for
groups of standard-sized patients and for broadly defined
types of equipment. These levels are expected not to be
exceeded for standard procedures when good and normal
practice regarding diagnostic and technical performance is
applied. For the reasons discussed above, the activities recom-
mended below for 99mTc-bisphosphonate should be consid-
ered only a general indication, based on data in the literature
and current experience. However, nuclear medicine physi-
cians in each country should respect the DRLs and the rules
set out in local laws.
For bone scintigraphy in adults, the average activity admin-
istered by a single intravenous injection should be 500 MBq
(300–740 MBq, 8–20 mCi; Table 1). The administered ac-
tivity usually ranges between 8 and 10 MBq/kg for adults.
Lower activities may be used when equipment with higher
detector sensitivity or resolution recovery resulting in similar
image quality is available. For markedly obese adult patients,
the administered activity may be increased to 11–13MBq/kg.
If the injected activity falls outside these recommended limits
for clinical reasons, the deviation should be kept as small as
possible. Practitioners could be required to justify administra-
tion of activities greater than local national DRLs.
The activities administered to children should be a fraction
of those administered to adults calculated in relation to body
weight according to the factors given by the EANM/SNMMI
Paediatric Dosage Harmonization Working Group [9, 48]. In
children, the EANM recommends a baseline activity of
35 MBq for 99mTc-bisphosphonates (with a minimum activity
of 40 MBq) that should be adjusted based on the class of the




Single-headed or dual-headed gamma camera equipped with a
low-energy, high-resolution parallel-hole collimator is
recommended. A low-energy general purpose collimator
may alternatively be used for early dynamic and blood pool
images. The energy window is centred on the photon energy
peak of 99mTc (140 keV) and the window width is generally
set at 15 % or 20%. An asymmetrical windowmay be used to
improve resolution (e.g. 20 % with a 3 % offset) but its use
must be supported by a physicist and an appropriately tailored
quality assurance programme [49, 50].
Planar and whole-body acquisitions
For the vascular phase of the examination, the camera is
positioned centred on the area of interest. The dynamic
acquisition of 30 to 60 images with a duration of 1 – 2 s
each and a matrix of 64 × 64 or 128 × 12 8 pixels is started
simultaneously with the intravenous tracer injection. The
early and late planar images are focused on one or more
region(s). The early images are acquired between 1 min
and 10 min after intravenous injection of 99mTc-labelled
bisphosphonate, with an acquisition time of 3 min to
5 min and a matrix size of 128 × 128 or 256 × 256.
Delayed images are usually acquired 2 h to 5 h after injec-
tion of the radiolabelled bisphosphonate using a predefined
duration (4 – 10 min) or number of counts, with a matrix
size of 128 × 128 or 256 × 256. When using a predefined
number of counts, at least 700,000 to 1,000,000 counts are
required for scanning the thoracoabdominal region, 250,
000 to 400,000 counts for the large joints and skull, and
150,000 to 250,000 for the distal joints, depending on the
field of view (FOV) of the gamma camera. The larger the
FOV, the larger the number of total counts required to give
similar count densities over equivalent regions of the skel-
eton [51]. Moreover, the presence of organs (typically the
kidneys) with physiologically high count densities may
hamper visualization of contiguous structures (typically
the spine).
A pinhole collimator acquiring high-resolution planar
views of a small area can be used to complete the examination,
particularly in infants and children. A total count of 50,000 to
100,000 is recommended. Zoom magnification or a converg-
ing collimator may also be used to improve resolution. The
physician interpreting the image should be notified when a
collimator that introduces distortions, such as a pinhole, has
been used. Additional projections, such as lateral, oblique,
tangential and special views may be obtained if necessary.
Table 1 Applicable dose
reference levels for bone
scintigraphy
Children Adults
3.5 kg 10 kg 20 kg 30 kg 40 kg 50 kg
Activity (MBq) 40 95 170 240 310 375 300 – 740
Effective dose (mSv) 2.0 2.4 2.5 2.6 2.7 2.8 2.9 – 4.0
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Whole-body bone scintigraphy can be accomplished with
multiple overlapping (spot) images or with continuous imag-
ing (i.e. whole-body scan) obtained in both anterior and pos-
terior projections. In adults, whole-body studies are currently
preferred. In children multiple planar acquisitions are com-
monly performed, rather than whole-body studies. When spot
views are used as the primary acquisition, the regions of skel-
eton covered by each spot viewmust overlap to avoid missing
any area.
Whole-body images are routinely acquired. Exceptions
may include the presence of localized symptoms or patient-
specific factors (children, or patients with severe pain or claus-
trophobia). The recommended scanning speed is 25–30 cm/
min for early-phase images (if applicable) and 10–15 cm/min
for delayed acquisitions. The scanning speed should be adjust-
ed so that routine anterior and posterior whole-body images
each contain more than 1.5 million counts. The image format
is 1,024×256 or 2,048×512. The whole-body images can be
processed with a spatial filter to improve pixel-to-pixel
variation.
It is often helpful to increase the time between tracer injec-
tion and image acquisition in order to optimize the bone-to-
background ratio, if the skeleton is poorly visualized (e.g.
renal insufficiency), for the imaging of specific anatomical
regions (e.g. the pelvis patients with urinary retention, or the
distal extremities in patients with peripheral circulatory disor-
ders), and in older patients with impaired bone metabolism
(osteoporosis, osteomalacia). Usually, the goal of these late
(6–24 h) images is to detect stress fractures, osteitis, osteo-
myelitis or bone metastases.
SPECT and SPECT/CT acquisitions
Diagnostic sensitivity and specificity of bone scanning can be
significantly increased by using SPECT or, if available,
SPECT/CT. Tomographic images may thus be acquired to
assist in localizing anomalies seen on the whole-body images
and to improve lesion contrast. In oncology, tomographic im-
ages should be used not only for better localization of unclear
lesions on planar images but also in patients with a high pre-
test probability of having bone metastases (for example, in
patients with increased tumour marker levels, recurrent can-
cer, or an advanced tumour that predominantly metastasizes to
bone etc.) [22, 52].
SPECT imaging should be performed as recommended by
the gamma camera manufacturer. In a typical acquisition pro-
tocol for a dual-headed gamma camera with the detector heads
oriented in a 180° geometry, a total of 60 or 64 frames per
detector head, each with duration of 10 to 30 s are acquired
over 360° into a 128×128 matrix (pixel size 4.6×4.6 mm).
An equivalent total number of counts should be acquired if
continuous acquisition is used.
SPECT/CT images are acquired using a multimodality
camera that combines a gamma camera and a multislice spiral
or flat panel/cone beamCTscanner (currently with 1, 2, 4, 6 or
16 slices). The CT scan is performed immediately before or
after the SPECT acquisition. The acquisition protocols are
specific to each type of machine. The CT component can be
performed either for attenuation correction and anatomical
localization or as an optimized diagnostic CT scan [53]. If
the CTscan is obtained for attenuation correction and anatom-
ical localization only, the use of a low milliampere-seconds
setting is recommended to decrease the radiation dose to the
patient. However, there are significant differences in operating
characteristics between types of scanner, hampering recom-
mendations on absolute values of milliampere-seconds.
Operators should be aware of the characteristics particular to
their scanner and understand the range of settings that are
consistent with meeting the required image quality and refer-
ence dose values. The use of intravenous iodinated contrast
material is generally not required, and MRI is preferred to
assess soft tissue disease.
The image matrix size is 512×512, with a tube voltage of
80–130 kV and intensity–time product of 2.5 to 300 mAs,
depending on the anatomical region being scanned and the
dose reduction software used. The pitch can range from 1 to
2 and the slice thickness is generally 0.33–2.0 mm for scan-
ning the extremities and 0.33 to 5 mm for the spine (Table 2).
The final image is obtained after applying a high-resolution
filter. The SPECT/CT acquisition may span a single FOV,
usually covering a region of 40 cm, or can include multiple
contiguous or separate FOVs.
Image processing
Planar images do not require particular processing. It should
be noted that current digital gamma cameras and workstations
allow changing the range of image contrast, improving the
diagnostic value of the images. In addition, this allows the
optimum contrast to be chosen for printing the images that
will be sent to the requesting clinician. A relative image quan-
tification may be performed on certain areas.
In the case of SPECT one should take into account the
different types of gamma camera and software available.
Reconstructions are preferably performed using the three-
dimensional (3D) iterative ordered subsets expectation
maximization algorithm (OSEM), including classical cor-
rections for attenuation and scatter, and nowadays also res-
olution recovery. The parameters used for reconstruction
may vary between vendors, but must permit a good image
resolution while maintaining adequate noise levels (using
postprocessing). Typically, three or five iterations are nec-
essary and eight to ten subsets. Postprocessing is usually
performed using a gaussian filter (width at half-maximum
of 4 to 10 mm), or a Butterworth filter (conventional
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parameters 10/0.5). Novel reconstruction algorithms, in-
cluding multimodal reconstruction, are being introduced
and alternatively can be used.
With a multimodality SPECT/CT system, coregistered and
aligned CT images, SPECT images and SPECT/CT fused im-
ages can be generated and visualized. The 3D images are
usually displayed as 2D orthogonal (axial, coronal and sagit-
tal) and maximum intensity projections. SPECT images with
and without attenuation correction should be available for
review. Care must be taken when judging attenuation-
corrected images since even slight misalignment between the
SPECTand CT images may cause attenuation and reconstruc-
tion artefacts, which can lead to overestimation or underesti-
mation of the tracer uptake in a certain region. Typical param-
eters used by the main multimodality camera manufacturers
are shown in Table 3.
Adapting scan parameters
The suggested imaging parameters may be adapted in consid-
eration of the specific clinical condition of the patient (e.g.
pain due to bone metastases, vertebral fractures, loosening
prosthesis, etc.). In such circumstances, shortening the dura-
tion of the examination by decreasing the time between injec-
tion and imaging, reducing the acquisition time, or increasing
the administered activity can be considered.
Selecting the appropriate image acquisition technique
1. Sequential planar acquisitions are used in the assessment
of various diseases: infectious or inflammatory diseases,
trauma, malignancy or pain syndromes affecting the
extremities.
2. Whole-body bone scintigraphy is routinely used in oncol-
ogy and other settings. In those cases, limited bone scan or
spot views are indicated only where an uptake abnormal-
ity or an equivocal finding detected on whole-body image
needs to be clarified.
3. Pinhole collimator acquisitions are preferentially reserved
for studies in children, and in particular for scanning the
hips (osteochondritis, aseptic necrosis).
4. Multimodality SPECT/CT imaging is indicated for the
assessment of lesions equivocal on planar bone scin-
tigraphy or localized pain syndromes with normal find-
ings on planar scintigraphy, in particular in the staging
of malignancies that have a tendency to metastasize to
bone [54]. SPECT/CT can also be used in patients with
multiple equivocal benign lesions in the axial or ap-
pendicular skeleton to increase specificity and diag-
nostic certainty.
Indications for SPECT/CT imaging
The indications for SPECT/CT imaging in daily clinical prac-
tice are broad and include (but may not be limited to) the
following:
1. Oncology: in case of abnormal planar scintigraphy to
improve lesion localization
2. Suspected traumatic injuries of the axial or appendicular
skeleton
3. Assessment of lesions in the tarsal or carpal small bones,
in particular after trauma
4. Suspicion of axial or peripheral osteoid osteoma
5. Assessment of the spine and sacroiliac joints in case of
rheumatic disorders
6. Diagnosis of osteonecrosis and bone infarction
7. Diagnosis of infectious lesions, such as osteomyelitis
and spondylodiscitis (complemented with infection
imaging)
8. Diagnosis of tendinitis
9. Evaluation of painful prosthesis
10. Evaluation of residual pain after orthopaedic surgery on
the axial or peripheral skeleton
11. Assessment of malignant or pseudomalignant lesions
12. Exploration of extraskeletal pathology or uptake
Table 3 Parameters from the
three main multimodality camera
manufacturers
Manufacturer
General electric Philips Siemens
Reconstruction algorithm OSEM 3D OSEM 3D OSEM 3D
Attenuation and scatter correction Yes Yes Yes
Resolution recovery Evolution Astonish Flash 3D
Parameters Three iterations Three iterations Five iterations
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Interpretation
Normal distribution of radiolabelled bisphosphonates
Bone scintigraphy is a very sensitive method for localization
of skeletal diseases, but the specificity may be low. Skeletal or
joint abnormalities should be interpreted taking into account
all available information, especially patient history, recent
findings, physical examination and other test or examination
results. Correct image interpretation requires detailed knowl-
edge of the normal dis tr ibution of radiolabelled
bisphosphonates. Particular attention should be paid to the
symmetry and homogeneity of tracer uptake. Image quality
should be assessed before starting to report scan findings
(Fig. 1).
Bone abnormalities
Both increases and decreases in tracer uptake have to be
assessed and any abnormality can be either focal or diffuse.
Focal or diffuse increased skeletal uptake can be objectively
assessed by comparison with the contralateral bone or soft
tissue. The localization, size, shape, intensity, and number of
abnormal findings should be described. In comparison to the
normal bone activity, increased tracer uptake indicates in-
creased osteoblastic activity. Some osteolytic skeletal lesions
appear as a region of reduced tracer uptake, either surrounded
by a rim of increased tracer deposition or, conversely, with a
punched-out appearance. Decreased uptake is less common
than focally increased activity and sometimes hard to identify.
Indeed, bone scintigraphy has a low diagnostic sensitivity for
purely osteolytic lesions (e.g. multiple myeloma).
Differential diagnosis can sometimes be based on the con-
figuration, location and number of abnormalities, although
most patterns are nonspecific. Lesions detected on bone scin-
tigraphy can take an extended time to normalize, reflecting the
protracted course of bone healing which may take many
months. Therefore, it is rarely useful to repeat an examination
within 4 or 6 months. In oncology, a decrease in intensity of
tracer uptake and in the number of abnormalities often indi-
cates improvement or may be secondary to focal therapy (e.g.
radiation therapy). An increase in the intensity or the number
of foci of increased uptake on scans performed less than
6 months apart may represent disease progression, but can
also be associated with a flare phenomenon [55].
Soft tissues findings
The renal system and urinary tract are also normally visualized
on the examination, as well as diffuse or focal tracer uptake in
the soft tissues. Tracer uptake in the kidney can be focal or
diffuse. A diffusely increased soft tissue uptake can be caused
by drug interference, failed 99mTc labelling, severe osteoporo-
sis, renal failure, dehydration, or an insufficiently long interval
between tracer injection and image acquisition. Conversely, a
low or absent tracer uptake in the soft tissues may be caused
by an excessive avidity for the tracer of osteoblasts populating
the axial skeleton, resulting in a Bsuper bone scan^ appearance
or an excessively long interval between tracer injection and
imaging.
Fig. 1 Normal whole-body scan.
Scintigraphic criteria allowing
assessment of the quality and in-
terpretability of a whole-body
scan
Eur J Nucl Med Mol Imaging (2016) 43:1723–1738 1733
Sources of error
Focal soft tissue hot spots have a wide range of causes, and
this may lead to an incorrect diagnosis of skeletal disease on
planar imaging. In striated muscle, for example, the causes of
increased uptake include the following:
& Repeated intramuscular injections of iron supplements
& Haematoma/necrosis/sickle cell anaemia
& Rhabdomyolysis (mechanical, toxic, electrical,…)
& Muscular abscess
& Primary tumours (rhabdomyosarcoma, other sarcomas)
& Metastases from solid tumours
& Poly(dermato)myositis (many causes)
& Severe renal insufficiency/hypercalcaemia/malignant
calcinosis/multiple myeloma
& Myositis ossificans
Attenuation artefacts caused bymetal parts or motion artefacts
are generally obvious, as is tracer extravasation at the injection
site due to (partly) paravenous injection.The most common
artefacts are related to urinary tracer contamination in patients
with dilatation, stasis or an anatomical variant of the urinary
tract, especially after urological surgery, or contamination dur-
ing urination. Imaging artefacts include the following:
& Injection artefacts.
& Imaging too early after injection, before the radiopharma-
ceutical has been optimally cleared from soft tissues.
& Greater than necessary collimator to patient distance.
& Patient movement.
& Pubic or sacral lesions obscured by superposition of blad-
der activity.
& Urine contamination or a urinary diversion reservoir.
& Changing bladder activity during SPECT of the pelvic
region.
& Purely lytic lesions with decreased or absent tracer uptake.
& Prosthetic implants, radiographic contrast materials or oth-
er attenuating artefacts which may obscure normal
structures.
& Homogeneously increased bony activity (e.g. ‘superscan’).
& Renal failure.
& Restraint artefacts caused by soft tissue compression.
& Significant findings outside the area of interest may be
missed if a limited study is performed.
& Prior administration of a higher-energy radionuclide, or of
a preceding examination with another 99mTc radiopharma-
ceutical that accumulates in an organ that could obscure or
confound skeletal activity.
& Radiopharmaceutical degradation.
Some bone lesions may be purely or predominantly lytic
and barely visible on planar bone scintigraphy when they are
small (<2 cm): multiple myeloma, infarction, osteonecrosis,
haemangioma, or lytic bone metastases. These artefacts and




The nuclear medicine physician should record a brief summa-
ry of the reason for the examination, the clinical problem, the
medical or surgical history, all relevant laboratory results and
radiological findings, and the treatments targeting or interfer-
ing with the osteoarticular system.
Procedure
Technical information should include the international non-
proprietary name (INN) of the radiolabelled bisphosphonate,
the injected activity in megabecquerels, the site and time of
injection, the time of image acquisition, the scanning protocol
used (early phase, late phase, SPECT/CT images), the differ-
ent image acquisitions, and the dose–length product (DLP)
and the CT dose index (CTDI) if SPECT/CT is performed.
Optionally, the model and installation date of the camera can
be stated. Also, any specific patient preparation should be
reported (analgesics, anxiolytics, catheter, etc.), in addition
to any incidents during imaging and any technical limitations
of the examination. The description of the different images
acquired during the examination includes details on early-
phase images, specific late-phase images, and whole-body
acquisitions. When multimodality SPECT/CT imaging is per-
formed, the description of osteoarticular structures focuses on
the SPECT images and the SPECT/CT fusion images.
Findings
Abnormal tracer uptake (increased, decreased, abnormal pat-
tern, bone findings, soft tissue findings) should be clearly
stated. If the study is a repeated examination, data are de-
scribed in correlation with other diagnostic results and in com-
parison with previous studies. Any skeletal anomalies that are
only seen on the CT part of the examination are also reported.
Likewise, other relevant nonskeletal pathology detected on
the CT images should be mentioned. Software-based assess-
ment of bone abnormalities can assist in reporting, but should
not replace assessment by a nuclear medicine physician.
Interpretation
The conclusion of the report should answer the question posed
by the referring clinician and should mention any associated
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diagnoses. A clear diagnosis should be given if possible, ac-
companied by a description of the study limitations when
appropriate. If the findings on scintigraphy or multimodality
imaging are nonspecific, a differential diagnosis should be
made, whenever possible mentioning the likelihood of the
listed diagnoses. When there is doubt as to the diagnosis or
further work-up is required, the nuclear medicine physician
may recommend additional tests (laboratory, imaging, biopsy,
etc.), especially if several differential diagnoses, which could
lead to different clinical management decisions, are possible.
If the scintigraphic findings and/or CT results reveal a life-
threatening disease or a condition that requires immediate ac-
tion, it is the nuclear medicine physician’s responsibility to
contact the referring clinician and organize urgent further care.
Quality control and improvement
Gamma camera quality control
A strict quality control programme should be routinely per-
formed [50] according to the rules of each country, as stated in
Council Directive 2013/59/EURATOM.
Quality control of the radiopharmaceutical
The radioactive concentration should be determined by mea-
suring the activity of the vial in a calibrated ionization cham-
ber. Labelling efficiency should be >95 %. The manufac-
turer’s instructions for assessment of radiochemical purity
(e.g. by thin-layer chromatography) and local laws should be
followed.
General safety procedures
Infection control, and patient education concerns
The injection must comply with local applicable guidelines
and recommendations. The needle used for tracer injection
must be collected in a needle container. Vials, syringes, injec-
tion needles and gloves used for injection are stored in lead-
shielded containers until safe radioactive levels are attained
(see Radiation protection). Side effects or incidents should
be reported in accordance with applicable laws.
Radiation safety
Physiological distribution of 99mTc-phosphonates
Phosphonates concentrate in the mineral part of bone, nearly
two thirds in hydroxyapatite crystals and one third in calcium
phosphate. Two major factors control the accumulation of
phosphonates in bone, namely blood flow and extraction effi-
ciency, which in turn depend on capillary permeability, acid–
base balance, parathyroid hormone levels, etc. Peak activity
through the kidneys is reached after approximately 20 min.
Radiation dosimetry
The organ that receives the largest dose of radiation is bone
(see table of adsorbed doses, ICRP no. 80, 1998) [56]. The
estimated adsorbed radiation doses to various organs in
healthy subjects following administration of 99mTc-labelled
phosphates and phosphonates are given in Table 4. It is as-
sumed that 50 % of the injected activity is absorbed by the
skeleton with an uptake half-life of 15 min, 15 % of the
injected activity is retained in the skeleton with a clearance
half-life of 2 h, and the remaining 35% of the injected activity
shows a clearance half-life of 3 days. In children, bone uptake
Table 4 Absorbed doses to various organs in healthy subjects following
administration of 99mTc-labelled phosphates and phosphonates according
to ICRP Publication 80
Organ Absorbed dose per unit activity
administered (mGy/MBq)
Adult 15 years 5 years
Adrenals 0.0021 0.0027 0.0058
Bladder 0.048 0.060 0.073
Bone surfaces 0.063 0.082 0.22
Brain 0.0017 0.0021 0.0043
Breast 0.00071 0.00089 0.0022
Gallbladder 0.0014 0.0019 0.0042
Stomach 0.0012 0.0015 0.0035
Small intestine 0.0023 0.0029 0.0053
Colon 0.0027 0.0034 0.0061
Heart 0.0012 0.0016 0.0034
Kidneys 0.0073 0.0088 0.018
Liver 0.0012 0.0016 0.0036
Lungs 0.0013 0.0016 0.0036
Muscles 0.0019 0.0023 0.0044
Oesophagus 0.0010 0.0013 0.0030
Ovaries 0.0036 0.0046 0.0070
Pancreas 0.0016 0.0020 0.0045
Red marrow 0.0092 0.010 0.033
Skin 0.0010 0.0013 0.0029
Spleen 0.0014 0.0018 0.0045
Testes 0.0024 0.0033 0.0058
Thymus 0.0010 0.0013 0.0030
Thyroid 0.0013 0.0016 0.0035
Uterus 0.0063 0.0076 0.011
Remaining organs 0.0019 0.0023 0.0045
Effective dose (mSv/MBq) 0.0057 0.0070 0.014
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concentrates in the metaphyseal growth zones, and this can
give rise to absorbed doses in these areas which are larger than
the average skeletal dose. In children with disease involving
higher uptake in bone and with severely impaired or without
renal clearance, the absorbed doses to bone surfaces and bone
marrow can increase by a factor of 2, resulting in an increase
in the effective dose by approximately 12 %.
The effective dose for an adult is in the order of 3–4 mSv
and in children 2.5 mSv (Table 1). The additional dose from
the CT scan is not taken into account in these figures. The
effective dose from the CT scan depends strongly on the ma-
chine used: for a diagnostic scan of the hips and spine the
effective dose can range between 4 and 10 mSv [57, 58].
The much lower milliampere-second values used for localiza-
tion or attenuation correction CT scans result in maximum
effective doses of 3 mSv. The effective doses for both types
of CT scan to the extremities are all less than 0.1 mSv.
Radiation protection
Staff radioprotection measures should follow the recommen-
dations for good practice (lead castle, syringe shields, wearing
gloves during tracer preparation and injection, etc.). The ex-
posure of caregivers on hospital wards is very low, and no data
are available to recommend any specific safety measures,
apart from those aimed at limiting contamination. It is recom-
mended that disposable gloves are worn for personal care
during the 24 h following the administration of radiopharma-
ceuticals labelled with 99mTc. Urine and feces can be disposed
of into the toilet. Pads, catheters and containers should be
handled with gloves. If hospital waste management accepts
only materials free of radioactivity, it is recommended that
for hospitalized patients all solid waste is collected for 3 days
and kept in storage for 4 days to allow sufficient decay of
radioactivity. For the patient’s family, no special measures
are required.
If tracer is administered erroneously to a patient for whom
the radiopharmaceutical was not intended, it is recommended
that the patient is sufficiently hydrated and encouraged to
urinate frequently, in order to limit the radiation dose to the
bladder and pelvis. No special radioprotection measures are
required if a patient dies.
Issues requiring further clarification
The role of 99mTc-phosphonate bone scintigraphy in follow-
up of treated cancer patients is still a matter of discussion.
There is general agreement that bone scintigraphy is indicated
in symptomatic patients. However, it is unproven whether
bone scintigraphy is cost-effective in all asymptomatic pa-
tients at risk of metastases (with worse prognostic factors). It
has not yet been established which subgroups of patients at
high risk of metastases may benefit from periodic bone scan
examinations. The list of indications for SPECT/CT has not
yet fully matured and more clinical trials are required before
further evidence-based guidelines can be produced. In addi-
tion, the optimal tube current and voltage settings for CTscans
performed for localization and attenuation correction remain
poorly defined and nonstandardized, requiring further study.
Disclaimer
The EANM wrote and approved these guidelines to promote
the use of high-quality nuclear medicine procedures. These
general recommendations cannot be applied to all patients in
all practice settings. The guidelines should not be deemed
inclusive of all proper procedures and exclusive of other pro-
cedures reasonably directed towards obtaining the same re-
sults. The spectrum of patients seen in a specialized practice
setting may be different from the spectrum usually seen in a
more general setting. The appropriateness of a procedure will
depend in part on the prevalence of disease in the patient
population. In addition, resources available for patient care
may vary greatly from one European country or one medical
facility to another. For these reasons, the guidelines cannot be
rigidly applied.
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